<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Coagulation factor Xa is the sole enzyme responsible for activating the zymogen prothrombin to thrombin, resulting in fibrin generation, platelet activation, and subsequent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="1" pm="."><plain>Our objective was to evaluate the antithrombotic efficacy of the novel factor Xa inhibitor, 2-(3-<z:chebi fb="0" ids="48090">carbamimidoyl</z:chebi>-<z:chebi fb="0" ids="22744">benzyl</z:chebi>)-3-[(3', 4'dimethoxy-<z:chebi fb="0" ids="17097">biphenyl</z:chebi>-4-<z:chebi fb="1" ids="23019">carbonyl</z:chebi>)-amino]-<z:chebi fb="4" ids="30772">butyric acid</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi>-<z:chebi fb="0" ids="27110">trifluoroacetate</z:chebi> (RPR208566), in a well-established rat model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, and to compare the results with those obtained with argatroban and <z:chebi fb="5" ids="28304">heparin</z:chebi>, direct and indirect inhibitors of thrombin, respectively </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation was initiated by placing a filter paper saturated with FeCl(2) on the adventia of the carotid artery for 10 min </plain></SENT>
<SENT sid="3" pm="."><plain>Time-to-occlusion was measured from initiation of injury until blood flow reached zero </plain></SENT>
<SENT sid="4" pm="."><plain>Formed <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were removed and weighed 60 min after the placement of the filter paper </plain></SENT>
<SENT sid="5" pm="."><plain>RPR208566, <z:chebi fb="5" ids="28304">heparin</z:chebi>, and argatroban dose-dependently increased time-to-occlusion and reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass </plain></SENT>
<SENT sid="6" pm="."><plain>When administered at 500 microgram/kg+50 microgram/kg/min, RPR208566 prolonged time-to-occlusion to 56+/-4 min (vs. 18+/-2 min for vehicle) and reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass to 3.0+/-0.7 mg (vs. 7.3+/-0.6 mg for vehicle) </plain></SENT>
<SENT sid="7" pm="."><plain>The highest doses of argatroban (500 microgram/kg+50 microgram/kg/min) and <z:chebi fb="5" ids="28304">heparin</z:chebi> (300 U/kg+10 U/kg/min) increased time-to-occlusion to the maximum of 60 min and decreased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass to 5.5+/-0.8 and 2.6+/-0.3, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The antithrombotic effects of <z:chebi fb="5" ids="28304">heparin</z:chebi> and argatroban at these doses were associated with increases in activated partial thromboplastin time of 5.6+/-0.9- and 2.9+/-0.3-fold over baseline, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>However, the highest dose of RPR208566 produced a modest 1.3+/-0.1-fold increase in activated partial thromboplastin time </plain></SENT>
<SENT sid="10" pm="."><plain>These results indicate that factor Xa inhibition with compounds such as RPR208566 may be an attractive mechanism for novel antithrombotic drug therapy </plain></SENT>
</text></document>